LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

Vertex Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

400.63 2.52

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

390.05

Max

401.42

Pagrindiniai rodikliai

By Trading Economics

Pajamos

387M

1B

Pardavimai

195M

3B

P/E

Sektoriaus vid.

27.771

35.733

Pelnas, tenkantis vienai akcijai

4.06

Pelno marža

34.84

Darbuotojai

6,100

EBITDA

641M

1.4B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+25.91% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-21B

100B

Ankstesnė atidarymo kaina

398.11

Ankstesnė uždarymo kaina

400.63

Naujienos nuotaikos

By Acuity

54%

46%

308 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-05 00:05; UTC

Karštos akcijos

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

2025-08-04 21:21; UTC

Uždarbis
Pagrindinės rinkos jėgos

Vertex Stock Falls After Pain-Drug Setback, Despite Stronger 2Q Earnings -- Update

2025-08-04 20:45; UTC

Uždarbis

Vertex Pharmaceuticals Swings to 2Q Profit as Sales Climb

2025-05-05 21:00; UTC

Uždarbis

Vertex Pharmaceuticals 1Q Sales Rise, Profit Falls on Impairment Charge

2025-08-05 20:44; UTC

Uždarbis

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

2025-08-05 18:17; UTC

Uždarbis

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

2025-08-05 15:25; UTC

Uždarbis

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

2025-08-05 14:12; UTC

Uždarbis

Vertex Stock Tumbles After Strong Earnings. What's Spooking Investors. -- Barrons.com

2025-08-05 11:27; UTC

Uždarbis

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

2025-08-05 10:55; UTC

Uždarbis

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

2025-08-05 10:36; UTC

Uždarbis

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

2025-08-05 10:18; UTC

Uždarbis

Vertex Stock Tumbles 15% After Strong Earnings. What's Spooking Investors. -- Barrons.com

2025-08-04 20:15; UTC

Uždarbis

Vertex Pharma: Guidance Includes Immaterial Cost Impact From Tariffs in 2025 Based on Currently Known Tariff Rates and Regulations >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharmaceuticals Reiterated FY25 Fincl Guidance >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: Mark Bunnage, D.Phil., SVP of Global Research, to Assume Role of CSO Effective Feb 1, 2026 >VRTX

2025-08-04 20:14; UTC

Uždarbis

Vertex Pharma: David Altshuler, Chief Scientific Officer, Intends to Retire Aug 1, 2026 >VRTX

2025-08-04 20:13; UTC

Uždarbis

Vertex Pharmaceuticals Backs FY25 Rev $11.85B-$12B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Net $1.03B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Adj EPS $4.52 >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q Rev $2.96B >VRTX

2025-08-04 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 2Q EPS $3.99 >VRTX

2025-05-06 16:31; UTC

Uždarbis

Vertex Pharmaceuticals Stock Is Tumbling After Earnings. Here's Why. -- Barrons.com

2025-05-05 20:03; UTC

Uždarbis

Vertex Pharmaceuticals Sees 2025 Rev $11.85B-$12B >VRTX

2025-05-05 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 1Q Net $646.3M >VRTX

2025-05-05 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 1Q Rev $2.77B >VRTX

2025-05-05 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 1Q EPS $2.49 >VRTX

2025-05-05 20:01; UTC

Uždarbis

Vertex Pharmaceuticals 1Q Adj EPS $4.06 >VRTX

2025-04-27 11:00; UTC

Svarbiausios naujienos

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

2025-04-11 09:30; UTC

Svarbiausios naujienos

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

Akcijų palyginimas

Kainos pokytis

Vertex Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

25.91% į viršų

12 mėnesių prognozė

Vidutinis 492.35 USD  25.91%

Aukščiausias 624 USD

Žemiausias 405 USD

Remiantis 24 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Vertex Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

24 ratings

14

Pirkti

10

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

428.545 / 498.65Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

308 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.